Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ...
Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex ...
Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...
NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) ...
The private school will open its first US campus in Long Island. Will it assimilate Americans into the upper crust – or is it more about branding? This fall, the British boarding school Harrow will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results